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In many countries, national vaccination recommen-
dations are developed by independent expert com-
mittees, so-called national immunisation technical 
advisory groups (NITAG). Since the evaluation of vac-
cines is complex and resource-demanding, collabora-
tion between NITAGs that evaluate the same vaccines 
could be beneficial. We conducted a cross-sectional 
survey among 30 European countries in February 
2014, to explore basic characteristics and current 
practices of European NITAGs and identify potential 
modes and barriers for collaboration. Of 28 respond-
ing countries, 26 reported to have a NITAG or an equiv-
alent expert group. Of these, 20 apply a systematic 
approach in the vaccine decision-making process, e.g. 
by considering criteria such as country-specific dis-
ease epidemiology, vaccine efficacy/effectiveness/
safety, health economics, programme implementa-
tion/logistics or country-specific values/preferences. 
However, applied frameworks and extent of evidence 
review differ widely. The use of systematic reviews is 
required for 15 of 26 NITAGs, while results from trans-
mission modelling and health economic evaluations 
are routinely considered by 18 and 20 of 26 NITAGs, 
respectively. Twenty-five countries saw potential for 
NITAG-collaboration, but most often named structural 
concerns, e.g. different NITAG structures or countries’ 
healthcare systems. Our survey gathered information 
that can serve as an inventory on European NITAGs, 
allowing further exploration of options and structures 
for NITAG collaboration.
Introduction
The number of vaccines available on the market has 
grown in recent years. At the same time, national 
healthcare systems have faced financial constraints 
and sought to maximise protection for those who 
benefit most in a given population. It has thus become 
increasingly important to assess the available evi-
dence regarding a range of aspects before introducing 
a new vaccine into national immunisation programs. 
The assessment usually takes into account the vaccine 
characteristics and expected population-level effects 
which can be considered as context-free aspects, e.g. 
vaccine efficacy/effectiveness or safety. Local dis-
ease epidemiology, cost-effectiveness and societal 
or cultural values and preferences, which are con-
sidered as context-specific aspects, are also factors 
often or always considered by responsible authorities. 
Assessments of vaccine recommendations should ide-
ally be standardised, transparent and evidence-based: 
evidence-based being defined as ‘the process of sys-
tematically finding, appraising, and using contempora-
neous research findings as the basis for (…) decisions’ 
[1].
To help appraising evidence gathered in such sys-
tematic manner, a number of tools are available for 
quality appraisal of single studies, e.g. the Critical 
Appraisal Skills Programme (CASP) [2], Assessing 
the Methodological Quality of Systematic Reviews 
(AMSTAR) [3], and the Cochrane risk of bias tool [4], as 
well as for entire bodies of evidence, such as the Grading 
of Recommendations Assessment, Development and 
Evaluation (GRADE) methodology [5,6].
In the majority of industrialised countries, national 
vaccine recommendations are developed by a national 
immunisation technical advisory group (NITAG) [7]. A 
NITAG is an independent expert advisory committee, 
providing ‘evidence-based recommendations to the 
Ministry of Health (MoH), policy makers and program 
managers to guide policies and formulate strategies’ 
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[8]. The World Health Organization (WHO) Global 
Vaccine Action Plan 2011–2020 stated as first strategic 
objective that all countries should as a priority com-
mit to immunisation, e.g. by strengthening national 
capacity through creating or strengthening existing 
independent bodies such as NITAGs to formulate evi-
dence-based policies [9].
During the ‘1st international workshop on procedures 
for the development of evidence-based vaccination rec-
ommendations’ in Berlin in 2010 [10], a working group 
of international experts involved in vaccine decision-
making processes discussed the need for international 
cooperation in the development of evidence-based 
vaccine recommendations and how such cooperation 
could be organised. Participants pointed out that, 
for example, systematic reviews of the same body of 
evidence are performed by NITAGs of several coun-
tries, thereby duplicating efforts and that this could 
be avoided by sharing those reviews and making them 
publicly available.
However, NITAG mode of operation, role and proce-
dures in the decision-making processes can differ sub-
stantially from country to country [11, 12]. Therefore, it 
is a prerequisite for the potential establishment of an 
international cooperation to examine in detail similari-
ties and differences in NITAGs’ structures and modes 
of practice. The survey conducted by Nohynek et al. in 
2013 was a first step taken to comprehensively explore 
key characteristics of NITAGs in the European Union 
(EU) and European Economic Area (EEA) countries and 
to explain obvious differences in immunisation policies 
between these countries even though decisions were 
based on the same or similar body of evidence [12]. In 
2014, as part of the Vaccine European New Integrated 
Collaboration Effort (VENICE) [13], an EU/EEA Member 
States network of experts in vaccine-preventable dis-
eases, we conducted a follow-up survey in order to 
(i) systematically collect basic characteristics of EU/
EEA countries’ NITAGs or immunisation expert groups, 
(ii) explore in detail their current practices for vaccine 
recommendation and, if applicable, framework char-
acteristics, and (iii) identify potential synergies and 
Table 1
General characteristics of National Immunisation Technical Advisory Groups and equivalent expert groups, European 
Union and European Economic Area countries, April 2014 (n=26)
Parameter Countries (n)
Expert body for national vaccine recommendations in place 26
Self-designationa as NITAG 21
Self-designationa as expert group 5




No fixed number 3
Years since NITAG/expert group was established 
< 5 years 5
5–20 years 12
> 20 years 9
NITAG/expert group members have to declare potential conflict of interest 20
NITAG/expert group chair is
Appointed by Ministry of Health or other/subordinate institution 20
Selected by NITAG/expert group members 5
No official chair 1
NITAG/expert group has voting members fromc
National public health institute (or equivalent) 15
Ministry of Health 13
Neither Ministry of Health nor national public health institute (or equivalent) 5
NITAGs/expert groups with Executive Secretariat or administrative office 17
NITAGs/expert groups with additional persons/institutes scientifically supporting their work 20
NITAGs/expert groups with official website 11
Providing English translations of NITAG/expert group information or materials (only non-English speaking countries) 2
NITAG: National Immunisation Technical Advisory Groups.
a  Classification as NITAG or expert group by respondent.
b  Might not include additional, ad hoc meetings.
c  Multiple answers possible.
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resource sharing as well as potential barriers and limi-
tations for collaboration in the vaccine recommenda-
tion development processes of NITAGs.
Methods
The VENICE gatekeepers in all 27 EU countries (except 
for the new Member State Croatia) and in the three EEA 
countries Iceland, Liechtenstein and Norway were con-
tacted via email and asked to nominate and provide 
contact information of an expert in their respective 
country involved in the national vaccine recommenda-
tion decision-making process. The criterion for nomina-
tion was being a member of the NITAG (preferentially 
the NITAG chair) or alternatively, being a staff mem-
ber of the NITAG Executive Secretariat (if existing). If 
the country had no NITAG, the gatekeeper was asked 
to nominate an expert involved in the development of 
national vaccine recommendations.
An electronic questionnaire was developed, piloted by 
staff of the Executive Secretariat of the German NITAG, 
and sent out via email to the nominated contact per-
sons in February 2014. The questionnaire consisted 
of four sections: (i) general NITAG characteristics, (ii) 
vaccine recommendation process, (iii) potential for col-
laboration between NITAGs in the vaccine recommen-
dation development process, and (iv) an open section 
for further explanations. Completed questionnaires 
were sent back to the Robert Koch Institute by the end 
of April 2014, assessed for completeness and consist-
ency, and in case of unclear answers or open ques-
tions a follow-up telephone interview was conducted 
or an email was sent if only minor clarifications were 
necessary.
For each country a two to three-page country profile 
was constructed with all information on the NITAG 
characteristics and decision-making processes, which 
was then supplemented with additional data regarding 
NITAG characteristics (year NITAG/expert group was 
established, voting-member composition, declaration 
of conflict of interest, number of meetings held, meet-
ings opened to public, minutes published online) from 
the first survey of Nohynek et al. [12] and then sent 
back to each respondent for validation [14].
Answers provided in response to the first two sections 
as well as parts of the third section were analysed 
quantitatively to obtain aggregated results describing 
key parameters of NITAGs/expert groups in Europe. The 
remaining data from the third section (open questions 
on potential and barriers/limitations for collaboration), 
and if applicable answers from the last section were 
analysed qualitatively.
Results
In total 28/30 countries responded to the question-
naire: Austria, Belgium, Bulgaria, Cyprus, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, 
Greece, Iceland, Ireland, Italy, Latvia, Liechtenstein, 
Lithuania, Malta, the Netherlands, Norway, Poland, 
Portugal, Romania, Slovakia, Slovenia, Spain, Sweden 
and the United Kingdom (UK). Hungary and Luxembourg 
did not participate in the survey. Of the 28 responding 
countries, 26 reported having a NITAG or an equivalent 
expert group in place. Liechtenstein did not have a 
NITAG or expert group but adopted vaccination recom-
mendations from the neighbouring Switzerland without 
additional in-country assessments. Liechtenstein was 
therefore not included in the final analysis of NITAGs. 
For Cyprus whose NITAG was discontinued in 2013, 
only data from the section regarding potential NITAG 
collaboration (see Attitudes towards and potential 
modes and barriers for collaboration) were included in 
the result section. At the time of our survey only a tem-
porary, ad hoc committee was in place and new Terms 
of References for the future NITAG were under inter-
nal discussion. Of the 27 countries (including Cyprus) 
overall participating in the survey, the respondents 
were either members of the respective NITAG or staff of 
the NITAG executive secretariat (n = 19), or staff of the 
National Public Health Institute or MoH (n = 8) involved 
in NITAG work or national immunisation policy.
Table 2
Professional expertise represented among National 
Immunisation Technical Advisory Groups and equivalent 
expert groups, European Union and European Economic 
Area countries, April 2014 (n = 26)







Microbiology including virology 17
University faculty/various disease specialists 6
Health economics 5
General practice 5
Regulatory authority on medicines 3
Evidence-based medicine/systematic reviews 2
Non-governmental organisations 2
School health medicine 2
Social sciences 2
Ethics 1






NITAGs: National Immunisation Technical Advisory Groups.
a Multiple answers possible.
b Representative from the Association of Pharmaceutical 
Companies
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Characteristics of NITAG/expert groups and 
funding of recommended vaccinations
Table 1 depicts general characteristics of the 26 NITAGs/
expert groups such as number of years since its estab-
lishment, whether members have to declare potential 
conflicts of interest, or if the NITAG is supported by 
an executive secretariat. A large range of professional 
expertise is usually represented among NITAGs/expert 
groups (Table 2). In 15 countries staff from the National 
Public Health Institute or an equivalent institution is 
also represented as a voting member in the committee 
(Table 1). 
The role of NITAGs/expert groups can be different dur-
ing the decision-making process of a national vaccine 
introduction in EU/EEA countries (Figure). Most com-
monly, NITAGs/experts groups provide advice to the 
National Public Health Institute or the MoH. The lat-
ter, often together with other stakeholders, usually 
makes the final decision whether or not a new vaccine 
Table 3
Elements of the vaccine recommendation development processes in National Immunisation Technical Advisory Groups and 
equivalent expert groups, European Union and European Economic Area countries, April 2014 (n=26)
Parameter Countries (n)
Systematic reviews
Use of systematic reviews in the recommendation development process is for NITAG/expert group
Required 15
Optionala 10
Systematic reviews not used 1
NITAG/expert group usually uses
Self-conducted systematic reviews and published systematic reviews by others (e.g. Cochrane Collaboration) 17
Data used  
Peer-reviewed data 17
Unpublished/non-peer reviewed data 9
Quality appraisal tools used 5
GRADE [5,6] 4
CASP [2] 2
Cochrane risk of bias tool 1
Only published systematic reviews by others 8




NITAG/expert group is allowed to outsource reviews to a third party (e.g. institution, private company) 8
Quality of evidence appraisal is performed 5
Contract allows to share results with other parties (e.g. foreign NITAGs or national public health institutes) 5
Transmission modelling 
Transmission modelling considered as part of the recommendation development process 18
Transmission modelling outsourced (e.g. national public health institute or similar institute) 15
Transmission modelling developed within NITAG/NITAG executive secretariat 8
Experiences exist with adopting existing models to own local setting 7
Health economic evaluations  
Health economic evaluations considered as part of the recommendation development process (e.g. cost-effectiveness analyses) 20
Level at which the economic evaluation is considered
NITAG/expert group 16
Ministry of Health or government or parliament or Ministry of Finance (or similar) 14
Economic assessment contains cost-effectiveness threshold 5
Cost-effectiveness threshold is final/decisive criterion 2
AMSTAR: Assessing the Methodological Quality of Systematic Reviews; CASP: Critical Appraisal Skills Programme; GRADE: Grading of 
Recommendations Assessment, Development and Evaluation; NITAG: National Immunisation Technical Advisory Groups; PRISMA: Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses.
a Usually or often conducted or if resources permit.
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is introduced in the national immunisation programme 
or vaccination schedule.
Funding of vaccinations that are adopted into the 
national vaccination schedule is in 19 countries through 
tax revenue, in three through social insurance, and in 
four based on a mixed scheme. In some countries, the 
funding can be restricted to mandatory vaccinations 
only and other recommended (but non-mandatory) vac-
cinations have to be paid out-of-pocket. Twenty-three 
of the 26 participating countries have a tender system 
for vaccine procurement in place, either at national 
(n = 20), regional (n = 4) and/or at local level (n = 2).
Frameworks/processes for evidence assessment
Of the 26 countries that participated in this survey sec-
tion, 20 indicated that their NITAG/expert group applies 
a systematic approach (e.g. framework or standard 
operating procedure) and 13 stated that the approach 
contained a fixed list of key criteria. Elements of those 
systematic approaches and fixed lists of key criteria, 
respectively, were the consideration of country-spe-
cific disease epidemiology and burden (n = 20), vac-
cine efficacy/effectiveness and safety (n = 16), health 
economic evaluations (n = 12), vaccine implementation, 
logistics and availability (n = 11), country-specific val-
ues and preferences and acceptability in target groups 
(n = 9), alternative preventive measures (n = 4), as well 
as experiences of other countries or WHO guidelines 
(n = 4).
Despite the consideration of these common key cri-
teria, the working process or sequences varied, from 
e.g. one NITAG with an assessment of the local disease 
Figure
Role of National Immunisation Technical Advisory Groups and equivalent expert groups in the decision making process of 
a national vaccination introduction, European Union and European Economic Area countries, April 2014 (n = 26) 
NITAG/Expert group 
Vaccine introduction into the national vaccination schedule/programme 
Ministry of Health 
In combination with other 
stakeholders 
(e.g. regional authorities, 
Ministry of Finance) 
National public











 n=1  
 








NITAG: National Immunisation Technical Advisory Groups.
a Ministry of Health is obliged to introduce the vaccine if it is recommended by the NITAG and is cost-effective.
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epidemiology and WHO recommendations to another 
NITAG that uses an approach with two prerequisites 
that have to be fulfilled i.e. vaccine is available and 
vaccine should induce more than a short-term immu-
nity, followed by the assessment of three criteria and 
13 aspects set by law. Further details of the different 
systematic approaches by country have been made 
publicly available in country-specific profiles [14].
Nine of the 20 countries with a framework had it pub-
lished [15–25], two of them in peer-reviewed journals 
[16,23].
The use of systematic reviews is required in 15 of the 
26 of NITAGs/expert groups, for the remaining this is 
optional (Table 3). Most NITAGs/expert groups (n=17) 
make use of self-conducted and published system-
atic reviews, and quality appraisal tools are used by 
five NITAGs/expert groups. The majority incorporates 
transmission modelling (n=18) and health economic 
evaluations (n=20) in their decision-making process. A 
background paper with the decision rationale is usu-
ally published by 13 NITAGs/expert groups. Of those 
published background papers, nine usually contain 
references of literature used, eight a narrative sum-
mary, six detailed results of systematic reviews includ-
ing meta-analysis and six other materials (multiple 
answers possible); two contain all of the above. It has 
to be noted that background paper publications may 
be either peer-reviewed or non-peer reviewed online 
publications, e.g. on the NITAG’s/expert group’s own 
website.
Attitudes towards and potential modes and 
barriers for collaboration
Of the 27 countries that responded, 25 thought that 
there is ‘potential for a collaboration/resource-sharing 
between NITAGs to support the individual country’s 
process of developing vaccination recommendations’. 
Regarding areas or aspects for collaboration, five of 
them named systematic literature reviews in general. 
Fourteen of the 25 countries explicitly mentioned 
collaborating in the evidence review of context-free 
aspects like vaccine efficacy/effectiveness or safety, 
and 19 of context-specific aspects (e.g. local disease 
burden or local cost-effectiveness).
Regarding the latter, one country stated that ‘there 
is always a value to also share the context-specific 
aspects’, another that ‘context-specific material may 
be illustrative of possible interpretations, assess-
ments and recommendations’. Cost-effectiveness and/
or transmission modelling were explicitly named by 15 
countries and disease burden assessment by 11 coun-
tries. It was suggested that ‘mathematical models and 
cost-effectiveness models could be shared in order 
to be adapted to every specific country’ and that ’(…) 
burden assessment templates and mathematical mod-
elling templates [should be shared] in which specific 
assumptions and country data could be introduced’.
When asked about minimum requirements for con-
ducting joint systematic reviews, transmission model-
ling and/or economic evaluations, 18 of 25 countries 
favoured agreed methodologies and written guide-
lines. However, while most only mentioned that there 
should be such agreed methodologies, some countries 
voiced more detailed ideas about the optimal content 
of those agreements: ‘Collaborating NITAGs should 
have the possibility to give input in the beginning of 
the process, e.g. which outcomes should be consid-
ered in the review or inclusion/exclusion criteria of 
studies’, and a common methodology should include 
‘e.g. a search strategy, paper selection, and exclusion 
criteria of publications’, make ’(…) use of the same 
tools, e.g. GRADE, AMSTAR etc.’ and should ‘(…) guar-
antee high quality of the work, for better comparabil-
ity and to make the review process more transparent’. 
Finally, one country mentioned that there should also 
be ‘a plan for peer review/publication’ of those collabo-
rative/shared systematic reviews to make transparent 
what is currently being worked on.
Regarding barriers and limitations for collaboration, 
responses could be grouped into the different catego-
ries (i) structural concerns, (ii) lack of funding and/
or lack of (human) resources and/or lack of available 
expertise, and (iii) possible language barriers and cul-
tural differences, mentioned by 16, 10 and two coun-
tries, respectively.
In terms of structural concerns the countries high-
lighted either limiting differences in the countries’ 
healthcare systems/vaccine delivery structures or dif-
ferences among countries regarding the respective role 
of the NITAG and NITAG (working) structures. Concern 
was expressed ’when the collaboration exceeds the 
technical level’ or that ‘tasks of the vaccination recom-
mendation development process can be in different 
institutions; close collaboration [among those intra-
country institutions] would be necessary which is often 
yet not present’. Furthermore, ‘NITAGs/MoH put differ-
ent value on the methodological requirements in the 
process of developing NITAG recommendations due 
to differences in the available resources but also due 
to different consequences of the NITAG recommenda-
tions. … [If the NITAG decision] automatically triggers a 
coverage decision by health insurances, there is much 
more of a need to apply rigorous methodologies and be 
transparent as much as possible’. Another point made 
by countries was that NITAGs might not always work on 
the same topic(s): ’(…) countries might be in a different 
process, one is considering a vaccination while another 
one is considering another one. However, this should 
still not hinder collaboration. When a country is con-
sidering to assess [a specific] vaccination, a request 
could be sent out for collaboration. And the result of 
the assessment should be shared.’
Lack of funding, lack of human resources or lack of 
available expertise was mostly mentioned by smaller 
countries or countries with fewer resources. Concern 
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was expressed that countries with no/little resources 
will not be able to contribute much and might therefore 
not be part of a common collaborative effort.
In respect to possible language barriers and cultural 
differences one country e.g. expressed the view that 
different values and preferences might lead to a dif-
ferent assessment of available evidence and conse-
quently different recommendations: ‘This [vaccination 
recommendations including assessments of several 
subquestions, each of them with their own value judg-
ments], in our opinion, not only precludes grading of 
the recommendation, it also means that any assess-
ment can only partially rely on a systematic review or 
an economic model. Although it will be stimulating and 
useful to participate in any such collaborative effort, 
that effort will cover only part of the assessment.’
Finally, the survey assessed the countries’ interests 
in sharing information on current NITAGs’ activities or 
outputs, asking to rate its helpfulness on a scale from 1 
(not necessary at all) to 5 (very helpful). An institutional 
platform hosting ‘Systematic reviews jointly conducted 
or outsourced by a group of European NITAGs’ scored 
a median of 4, ‘Information on vaccine recommenda-
tions/assessments of the different European NITAGs 
currently in progress’ and ‘Information on European 
NITAGs’ priorities for vaccine recommendations that 
need to be dealt with’ both scored a median of 5.
Discussion
This survey gathered information from 28 of 30 EU/ 
EEA countries, thereby allowing for a detailed and rep-
resentative inventory of NITAGs and equivalent expert 
groups involved in the process of developing national 
vaccination recommendations in the EU/EEA. In our 
survey, 26 of the participating countries reported hav-
ing a NITAG or equivalent expert group, and the number 
will rise further once Cyprus has finished the process 
of re-establishing its NITAG. Liechtenstein relies on the 
evidence-based recommendations of the Swiss NITAG 
[26], an alternative approach for very small countries 
also proposed by the WHO [8].
Twenty of the surveyed countries indicated that they 
apply a systematic approach when developing a vac-
cination recommendation. The approaches reported 
by all/most of countries include an assessment of 
country-specific disease epidemiology/burden and 
vaccine efficacy/effectiveness and safety. About half 
also assess context-specific questions regarding pro-
gramme implementation and vaccine logistics as well 
as potential acceptability in the target population. 
However, some countries have, as part of their specific 
formal requirements, a comprehensive set of questions 
or topics that need to be addressed in a predefined 
sequence. Furthermore, five countries use quality of 
evidence assessment tools. The extent and specif-
ics that NITAGs/expert groups apply such systematic 
approaches, rely on systematic reviews, and consider 
results from transmission modelling and health eco-
nomic evaluations differ between countries. Reasons 
for these differences are diverse and may be rooted 
in the role of the NITAG/expert group decision-making 
process. For example, if the NITAG is the final decision-
maker for inclusion of a vaccine in the national pro-
gramme, the NITAG might feel a stronger responsibility 
to apply rigorous methodologies and to be as trans-
parent as possible. Other reasons for these diversities 
might be cultural variations among countries regarding 
societal or governmental value/demand of transpar-
ency and evidence-based approaches vs trust in expert 
opinion as well as different resources for the NITAGs 
(e.g. the existence of an executive secretariat, own 
budget, or other contributing institution) or historical 
developments.
Less than half of the countries with a framework had 
it published, which makes it difficult to assess their 
differences in detail. Of those countries with a pub-
lished framework, only Finland and the Netherlands 
[16,23] published it in English in peer-reviewed jour-
nals, thereby making it accessible for a wider audi-
ence. The remaining frameworks were published on 
websites associated with the NITAG/expert group or 
government, making it necessary to know specifically 
what and where to look for. Furthermore, four of those 
remaining seven frameworks are only available in the 
country’s language. In comparison, NITAG frameworks 
of Canada, Switzerland and the United States [26-30] 
and WHO SAGE [31] can easily be found in English in 
peer-reviewed journals.
Despite those framework differences and respond-
ents’ concerns especially about structural differences 
among NITAGs or country systems posing essential 
barriers for collaboration, all but two saw potential 
for collaboration or resource-sharing to support the 
individual countries’ processes of developing evi-
dence-based vaccination recommendations. The great 
majority would favour to collaborate in systematic 
reviews regarding context-free and context-specific 
aspects. Fundamental for such collaboration is to rec-
ognise, that – as suggested by the GRADE working 
group – two steps can be separated when developing 
a recommendation: The assessment of the body of evi-
dence and the process when moving from evidence to 
recommendation [5, 6]. Collaboration between NITAGs 
should focus on the first step. The strength of such an 
effort would be that it does not aim to harmonise vac-
cination recommendations across Europe and that it 
acknowledges that final decisions lie in the mandate 
of each country, with country-specific particularities 
being considered in their decision-making process.
Fifteen of the NITAGs/expert groups are required and 
ten optionally use systematic reviews in the recommen-
dation process. Thus it is not surprising that countries 
saw potential for collaboration in conducting system-
atic reviews, a time and resource consuming undertak-
ing, often requiring at least 12 months per review [32]. 
Though the majority favoured agreed methodologies 
and written guidelines as a minimum requirement, 
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only a small number of countries suggested possible 
concrete requirements, most likely to make the review 
process more transparent or applicable to their own 
framework requirements. Furthermore, so far the use 
of quality appraisal tools is not yet common among 
NITAGs/expert groups and is currently only performed 
by five countries. By definition, cooperation regard-
ing context-free aspects will be less of a challenge as 
results are usually easily transferrable across coun-
tries. Regarding context-specific aspects, respondents 
found it valuable to share tools or generic models, 
rather than results, so countries could then apply their 
own country-specific assumptions or epidemiologi-
cal data to these models. However, such adaptations 
of existing models could require special skills – so far 
seven countries have experiences of adopting exist-
ing models to their own local setting. Nevertheless, as 
one respondent stated, sharing context-specific infor-
mation could still be helpful in the decision-making 
process, as it can provide an illustration of other coun-
tries’ assessments and interpretations.
Our survey has two main limitations. Though answers 
in the questionnaire were followed up by a telephone 
interview or email, language barriers or differences in 
cultural perception may have led to misunderstand-
ings of interview questions or responses. For example, 
the fact that in two countries transmission modelling 
was not named as part of the recommendation pro-
cess but health economic assessments was (though 
transmission modelling is usually necessary to con-
duct cost-effectiveness analyses) might indicate that 
respondents could have interpreted the two terms 
and what they comprise in different ways. However, 
to avoid misunderstanding, summarised answers by 
country were given to the respondent for final valida-
tion to minimize interview misunderstandings. Second, 
the views and attitudes towards collaboration were 
retrieved usually only from one expert per country and 
might not necessarily represent the view of the entire 
NITAG or other stakeholders involved in NITAG work. 
However, we believe that these views and information 
constitute an important starting point for further dis-
cussions and stakeholder involvement with the aim to 
develop a draft roadmap for NITAG collaboration and 
resource-sharing in the EU/EEA as currently envisioned 
by ECDC and the VENICE project partners.
In 2008, the Supporting National Independent 
Immunization and Vaccine Advisory Committees (SIVAC) 
initiative has founded a platform to support the estab-
lishment of NITAGs in low- and middle income coun-
tries by providing information, tools and short-learning 
modules [33]. In our survey, respondents showed great 
interest in an institutional platform that would go 
beyond what SIVAC is currently offering. Besides host-
ing a share point for already published materials, this 
platform could provide information on vaccine recom-
mendations and assessments currently in progress and 
on future priorities of European NITAGs/expert groups, 
could allow the sharing of not yet published outputs (if 
needed under specific confidentiality agreements), or 
could host or organise systematic reviews jointly con-
ducted (or outsourced) by NITAGs/expert groups. When 
provided with such a platform, NITAGs or expert groups 
could collaborate more easily, form small groups to 
conduct systematic reviews, share generic models, 
or benefit from work already done. However, such an 
approach requires addressing and solving a number 
of practical issues, e.g. finding a consensus on guide-
lines for systematic reviews, the application of qual-
ity appraisal tools, the issue of data protection and 
code of conduct for considering unpublished data, or 
who would host and, very importantly, maintain such 
an institutional platform. Furthermore, questions may 
arise about contribution equity or compensation, par-
ticularly concerning the conduct of resource-intensive 
systematic reviews or the development of transmis-
sion models. Small countries and countries with fewer 
resources have already identified a lack of expertise 
and/or human resources in their country as an impor-
tant potential barrier for collaboration. However, even 
countries with more resources or greater expertise will 
not be able to constantly provide output for all EU/EEA 
Member States. A conference with interested repre-
sentatives of all NITAGs/expert groups in the EU/EEA 
countries could provide a forum to discuss and start to 
resolve those challenging issues and thereby to define 
common standards for advancing and achieving future 
NITAG collaboration in Europe.
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